Access BNP Customer FAQs

Frequently asked questions for the Access BNP assay being directly sold by Beckman Coulter to customers

Thank you for advancing patient care with Beckman Coulter solutions. We are committed to providing the highest quality diagnostic solutions for our customers and are delighted to announce that on July 26, 2021, Beckman Coulter secured from Quidel Corporation the exclusive distribution rights of the lab-based B-type Natriuretic Peptide (BNP) assay, which is run on Beckman Coulter analyzers. The assay, branded today under Triage® BNP, will be rebranded going forward as “Access BNP”. As a valued customer, you will now receive BNP product and BNP technical support exclusively from Beckman Coulter or your Beckman Coulter authorized distributor. Based on a country by country schedule, Beckman Coulter and/or its authorized distributors will begin selling of the BNP product to you.

de Lemos J A, McGuire D K, Drazner M H. Btype natriuretic peptide in cardiovascular disease. Lancet 2003362316–322.This review summarises present knowledge on the physiology of BNP and provides comprehensive data on the diagnostic and therapeutic potential of BNP in patients with heart failure.